Newsletter
Industry Watch
As we move into the final week of February, we look at the latest news stories from around our industry. Stories about the application of gene…
All Insights
Newsletter
Newsletter
Industry Watch
As we move into week 7 of 2020, we bring you a selection of news stories based around neurological research. As cell and gene therapies advance, we…
Newsletter
Industry Watch
It's week 6 of 2020 and these are the biggest news stories from the life science industry. In this edition we bring news of a new gene correction…
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
Case Study
Overcoming Difficult Recruitment Challenges to Meet Vaccine Study Enrollment Goals
A randomized, observer-blind, placebo-controlled, multi-center, multi-national, Phase III trial evaluating the efficacy, immunogenicity, and safety…
Case Study
Succeeding with a Risk-Based Approach
A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe…
Case Study
Embracing a Risk-based Approach
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the…
Blog
Virtual Technology Strives to Make Better Research and Treatments for All
The use of virtual reality (VR) technology, wearable technology, and virtual clinical trials can provide researchers with a more convenient way to…
Fact Sheet
Patient Safety and Pharmacovigilance Agreements
Pharmacovigilance Agreements (PVAs) are agreements between two companies based on their Commercial Agreements that require an exchange of safety…
Fact Sheet
Aggregate Safety Reports
PRA Health Sciences (PRA) is dedicated to ensuring quality Aggregate Safety Reports are delivered to our sponsor and MAH partners. Our experienced…